Latest Annual Report
Filed: 2026-02-27
Key Insights
- The company has entered into a licensing agreement with Duke University to expand its umbilical cord blood and cord tissue stem cell service offerings, which could drive future growth.
- The company has issued amended and restated promissory notes and made changes to its Susser Bank credit agreement, suggesting potential financing activities or debt restructuring.
- The company has granted various stock options and restricted shares to its executives and employees, which could indicate changes in its compensation and incentive structure.